Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia
DYSMOT-RIII
Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia
1 other identifier
observational
75
1 country
1
Brief Summary
Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms from the gastroduodenal region in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. FD can be further subdivided into two diagnostic categories: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Disorders of gastric electric activity and abnormal gastric emptying are probably actively involved in the FD onset. Different noninvasive procedures may be applied in order to evaluate the gastric motor functions such as 13C breath testing and cutaneous electrogastrography. Besides, different gastrointestinal peptides (i.e. CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II) are involved in the control of gastroduodenal motility. Aims of the present study are: 1) to evaluate the GI peptide circulating concentrations, the gastric electrical activity and gastric emptying time by applying noninvasive procedures in patients suffering from functional dyspepsia and 2) to test whether a significant difference exists between the two diagnostic categories of meal-induced dyspeptic symptoms
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 26, 2014
CompletedStudy Start
First participant enrolled
April 1, 2014
CompletedFirst Posted
Study publicly available on registry
April 14, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedSeptember 2, 2015
September 1, 2015
7 months
March 26, 2014
September 1, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fasting plasma concentration of GI peptides, gastric emptying time and dyspepsia subtype.
Exploration of relationships between GI peptide concentrations (CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II), solid gastric emptying, and dyspepsia subtype. Blood samples will be compared pre/post test meal for FD cohorts (EPS/PDS) and controls: 0 time/baseline and 16 times/post meal. Associations of plasma GI peptides pre and postprandial levels \& gastric emptying will be studied. Amount of 13CO2 will be determined for each time point (1 pre/ 16 post meal) using equation nested in software package with IRMS. The concentration of 13CO2 and 12CO2 in the exhaled breath samples will be measured by mass spectrometry.
Duration of 4-hour study visit
Secondary Outcomes (1)
Gastric electrical activity and GI peptides according functional dyspepsia subtype
Duration of 4-hour study visit
Study Arms (3)
Epigastric pain syndrome (EPS)
Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
Postprandial distress syndrome (PDS)
Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
Healthy subjects
Healthy subjects as control group
Eligibility Criteria
Patients will be recruited in this observational study from the out-patients of the National Institute of Digestive Diseases, I.R.C.C.S. Saverio de Bellis, Castellana Grotte, Bari, Italy.
You may qualify if:
- Patients suffering from dyspeptic symptoms according to Rome III;
- Helicobacter pylori negative subjects;
- age 19-70 yr.;
- willingness to complete the study;
- not recent administration (in the 2 months before the examination) of anti-inflammatory drugs (NSAIDs), antibiotics, bismuth, antacids, H2-receptor antagonists, proton pump inhibitor, sucralfate or misoprostol;
- at least one endoscopic/radiological GI evaluation in the last 5 yrs.
You may not qualify if:
- previous history of gastric tumors or gastric surgery
- lactose intolerance;
- celiac disease, wheat sensitivity;
- alarm symptoms (GI bleeding, weight loose etc.);
- psychiatric diseases;
- familial history of peptic ulcer;
- gastric cancer or IBD;
- abnormal thyroid function;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institute of Digestive Diseases IRCCS "Saverio de Bellis"
Castellana Grotte, Bari, 70013, Italy
Related Publications (5)
Chasen M, Bhargava R. Gastrointestinal symptoms, electrogastrography, inflammatory markers, and PG-SGA in patients with advanced cancer. Support Care Cancer. 2012 Jun;20(6):1283-90. doi: 10.1007/s00520-011-1215-8. Epub 2011 Jun 19.
PMID: 21688162BACKGROUNDMiwa H, Watari J, Fukui H, Oshima T, Tomita T. [Pathogenesis and management of functional dyspepsia]. Nihon Rinsho. 2010 Jul;68(7):1391-401. Japanese.
PMID: 20662226BACKGROUNDKhoo J, Rayner CK, Feinle-Bisset C, Jones KL, Horowitz M. Gastrointestinal hormonal dysfunction in gastroparesis and functional dyspepsia. Neurogastroenterol Motil. 2010 Dec;22(12):1270-8. doi: 10.1111/j.1365-2982.2010.01609.x. Epub 2010 Oct 5.
PMID: 20939851BACKGROUNDDe Smet B, Mitselos A, Depoortere I. Motilin and ghrelin as prokinetic drug targets. Pharmacol Ther. 2009 Aug;123(2):207-23. doi: 10.1016/j.pharmthera.2009.04.004. Epub 2009 May 6.
PMID: 19427331BACKGROUNDGeeraerts B, Mimidis K, van Oudenhove L, Vos R, Karamanolis G, Tack J. Role of endogenous opioids in the control of gastric sensorimotor function. Neurogastroenterol Motil. 2008 Oct;20(10):1094-102. doi: 10.1111/j.1365-2982.2008.01144.x. Epub 2008 May 15.
PMID: 18482249BACKGROUND
Biospecimen
breath specimen, whole blood, serum, white cells.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francesco Russo, MD
IRCCS "S. de Bellis"
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior researcher
Study Record Dates
First Submitted
March 26, 2014
First Posted
April 14, 2014
Study Start
April 1, 2014
Primary Completion
November 1, 2014
Study Completion
June 1, 2015
Last Updated
September 2, 2015
Record last verified: 2015-09